PMID- 28514591
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 0890-9016 (Print)
IS  - 0890-9016 (Linking)
VI  - 31
DP  - 2015
TI  - Risk Stratification of Human Leukocyte Antigen Class II Donor Specific Antibody 
      Positive Patients by Immunoglobulin G Subclasses.
PG  - 293-301
AB  - BACKGROUND: Human leukocyte antigen (HLA) antibodies are a major cause of graft 
      loss in mismatched transplant recipients. However, the time to graft loss 
      resulting from antibody induced injury is unpredictable. The unpredictable nature 
      of antibodies may be related to the subclass of antibodies. In this study, HLA 
      immunoglobulin G (IgG) subclasses were investigated to determine whether a unique 
      IgG subclass composition could better identify those patients at eminent risk for 
      graft loss. METHODS: The serial serum samples from the 57 patients with 
      post-transplant HLA class II donor specific antibodies (DSA) were tested for the 
      three IgG subclasses (IgG1, IgG3, and IgG4). RESULTS: IgG3 and IgG4 were highly 
      prevalent in failed patients compared to functioning patients (82 % vs. 34%, 45% 
      vs. 20%, respectively). IgG3 development showed a distinct subclass trend between 
      failed and functioning patients with poor graft survival (log rank p=0.0006). 
      IgG1 was almost equally abundant in both groups (100% and 97%, respectively). Of 
      the 5 patterns of IgG subclass combinations observed, IgG1+3+ showed the 
      strongest association with graft failure (hazard ratio 3.14, p=0.007). 
      CONCLUSION: Patients with IgG3 subclass HLA DSA showed lower graft survival. 
      Post-transplant monitoring for IgG subclasses rather than total IgG monitoring 
      may identify patients at risk for graft failure.
FAU - Taniguchi, Michiko
AU  - Taniguchi M
AD  - City of Hope, Duarte, CA.
FAU - Rebellato, Lorita M
AU  - Rebellato LM
AD  - The Brody School of Medicine at East Carolina University, Greenville, NC.
FAU - Briley, Kimberly P
AU  - Briley KP
AD  - The Brody School of Medicine at East Carolina University, Greenville, NC.
FAU - Haisch, Carl E
AU  - Haisch CE
AD  - The Brody School of Medicine at East Carolina University, Greenville, NC.
FAU - Bolin, Paul
AU  - Bolin P
AD  - The Brody School of Medicine at East Carolina University, Greenville, NC.
FAU - Banuelos, Nubia
AU  - Banuelos N
AD  - Terasaki Foundation Laboratory, Los Angeles, CA.
FAU - Hopfield, Judy
AU  - Hopfield J
AD  - Terasaki Foundation Laboratory, Los Angeles, CA.
FAU - Terasaki, Paul I
AU  - Terasaki PI
AD  - Terasaki Foundation Laboratory, Los Angeles, CA.
FAU - Everly, Matthew J
AU  - Everly MJ
AD  - Terasaki Foundation Laboratory, Los Angeles, CA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Transpl
JT  - Clinical transplants
JID - 8812419
OTO - NOTNLM
OT  - Class II
OT  - HLA antibodies
OT  - IgG3
OT  - graft survival
OT  - subclass
OT  - transplantation
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
CRDT- 2017/05/18 06:00
PHST- 2017/05/18 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PST - ppublish
SO  - Clin Transpl. 2015;31:293-301.